Category: J Gastroenterol

Related Articles Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ). J Gastroenterol. 2018 Aug 14;: Authors: van der Sloot KWJ, Weersma RK, Dijkstra G, Alizadeh BZ Abstract BACKGROUND: In the complex etiology of inflammatory bowel disease (IBD), the exposome is a major contributor. Though many environmental exposures have been identified, quality of evidence varies greatly and overall evidence for the exposome is inconclusive. A universal, precise, and reproducible measurement tool is needed to study the exposome…

Related Articles The state of the art on treatment of Crohn’s disease. J Gastroenterol. 2018 Jul 06;: Authors: Shi HY, Ng SC Abstract Crohn’s disease (CD) is a chronic, progressive, and destructive disease of the gastrointestinal tract. Although its incidence appears to be stable or decreasing in most countries in the North America and Europe, the incidence is rising rapidly in Asian countries. Immunomodulators and biologics are increasingly used to avoid long-term bowel damage and subsequent disability. Therapeutic drug monitoring facilitates optimizing thiopurines and anti-TNFs use. New biologic agents targeting…

Related Articles Crohn’s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan. J Gastroenterol. 2018 Jun 09;: Authors: Yasukawa S, Matsui T, Yano Y, Sato Y, Takada Y, Kishi M, Ono Y, Takatsu N, Nagahama T, Hisabe T, Hirai F, Yao K, Ueki T, Higashi D, Futami K, Sou S, Sakurai T, Yao T, Tanabe H, Iwashita A, Washio M Abstract BACKGROUND: In this study, survival and cause of death were investigated in patients with Crohn’s disease (CD) at a tertiary referral center. METHODS: A database…

New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018 Mar 19;: Authors: Verstockt B, Ferrante M, Vermeire S, Van Assche G Abstract The advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD in the last 15 years, but primarily and more importantly secondary loss of response is often observed. Fortunately , new treatment options have been actively explored and some have already entered our clinical practice. In the class of anti-cytokine agents, the anti-IL12/IL23 monoclonal antibodies (mAbs) have entered clinical practice with the anti-p40 mAb ustekinumab in…

Related Articles Induction of PIR-A/B+ DCs in the in vitro inflammatory condition and their immunoregulatory function. J Gastroenterol. 2018 Mar 05;: Authors: Matsui F, Inaba M, Uchida K, Nishio A, Fukui T, Yoshimura H, Satake A, Yoshioka K, Nomura S, Okazaki K Abstract BACKGROUND: Dendritic cells (DCs), primary antigen-presenting cells, are now well known as an immunoregulator of many aspects of immune responses including inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis. We have reported that PIR-A/Bhigh cDCs (conventional DCs) appeared in dextran sodium sulfate (DSS)-induced colitis…

Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018 Feb 10;: Authors: Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T Abstract Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although…